Works by Jianping Xiong


Results: 122
    1
    2
    3
    4
    5

    Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double‐Blinded, Placebo‐Controlled, Randomized Phase III Trial (ALTER0703).

    Published in:
    Oncologist, 2021, v. 26, n. 10, p. e1693, doi. 10.1002/onco.13857
    By:
    • Chi, Yihebali;
    • Shu, Yongqian;
    • Ba, Yi;
    • Bai, Yuxian;
    • Qin, Baoli;
    • Wang, Xiuwen;
    • Xiong, Jianping;
    • Xu, Nong;
    • Zhang, Helong;
    • Zhou, Jianfeng;
    • Xu, Jianming;
    • Cheng, Ying;
    • Feng, Jifeng;
    • Hu, Chunhong;
    • Chen, Yigui;
    • Chen, Zhendong;
    • Wang, Jufeng;
    • Dang, Chengxue;
    • Wang, Jianhong;
    • Wan, Yiye
    Publication type:
    Article
    6
    7
    8
    9

    Standard: Human gastric organoids.

    Published in:
    Cell Regeneration, 2025, v. 14, n. 1, p. 1, doi. 10.1186/s13619-024-00218-6
    By:
    • Hong, Fan;
    • Tan, Ronghui;
    • Wang, Ting;
    • Zhong, Nanshan;
    • Zhao, Hongling;
    • Xu, Rui-hua;
    • Shen, Lin;
    • Liu, Yingbin;
    • Yao, Xuebiao;
    • Xiang, Dongxi;
    • Hui, Lijian;
    • Xiong, Jianping;
    • Gao, Dong;
    • Zhao, Bing;
    • Miao, Zhifeng;
    • Hao, Jie;
    • Li, Yong;
    • Hu, Shijun;
    • Fu, Boqiang;
    • Hua, Guoqiang
    Publication type:
    Article
    10

    Standard: Human gastric cancer organoids.

    Published in:
    Cell Regeneration, 2024, v. 13, n. 1, p. 1, doi. 10.1186/s13619-024-00217-7
    By:
    • Tan, Ronghui;
    • Hong, Fan;
    • Wang, Ting;
    • Zhong, Nanshan;
    • Zhao, Hongling;
    • Xu, Rui-hua;
    • Shen, Lin;
    • Liu, Yingbin;
    • Yao, Xuebiao;
    • Xiang, Dongxi;
    • Gao, Dong;
    • Xiong, Jianping;
    • Hui, Lijian;
    • Zhao, Bing;
    • Miao, Zhifeng;
    • Hao, Jie;
    • Li, Yong;
    • Hu, Shijun;
    • Fu, Boqiang;
    • Hua, Guoqiang
    Publication type:
    Article
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43

    First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial.

    Published in:
    Signal Transduction & Targeted Therapy, 2025, v. 10, n. 1, p. 1, doi. 10.1038/s41392-025-02229-4
    By:
    • Shi, Yuankai;
    • Ba, Yi;
    • Wang, Junye;
    • Xiong, Jianping;
    • Gu, Kangsheng;
    • Chen, Yigui;
    • Zheng, Zhendong;
    • Wang, Zishu;
    • Guo, Weijian;
    • Cheng, Ying;
    • Yin, Xianli;
    • Liu, Yunpeng;
    • Bai, Yuxian;
    • Li, Enxiao;
    • Li, Qi;
    • Zhu, Liangjun;
    • Li, Wei;
    • Jiang, Da;
    • He, Jingdong;
    • Chen, Jiansi
    Publication type:
    Article
    44
    45
    46
    47
    48
    49
    50